Evolus Inc
EOLS6.900USD
+0.050+0.73%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
446.89MMarket Cap
LossP/E TTM
More Details of Evolus Inc Company
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Evolus Inc Info
Ticker SymbolEOLS
Company nameEvolus Inc
IPO dateFeb 08, 2018
CEOMoatazedi (David)
Number of employees332
Security typeOrdinary Share
Fiscal year-endFeb 08
Address520 Newport Center Dr Ste 1200
CityNEWPORT BEACH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92660-7022
Phone19492844555
Websitehttps://www.evolus.com/
Ticker SymbolEOLS
IPO dateFeb 08, 2018
CEOMoatazedi (David)
Company Executives of Evolus Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
62.24%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
8.84%
Tang Capital Management, LLC
8.47%
Lynch (Timothy Patrick)
7.92%
Caligan Partners, LP
6.39%
BlackRock Institutional Trust Company, N.A.
6.15%
Other
62.24%
Shareholder Types
Shareholders
Proportion
Hedge Fund
38.96%
Investment Advisor
22.15%
Investment Advisor/Hedge Fund
15.60%
Individual Investor
10.06%
Private Equity
4.06%
Corporation
3.30%
Research Firm
2.38%
Pension Fund
0.47%
Bank and Trust
0.30%
Other
2.73%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
356
58.38M
89.22%
--
2025Q3
366
58.59M
90.20%
-409.50K
2025Q2
368
58.97M
91.09%
+3.93M
2025Q1
354
55.05M
88.70%
-1.35M
2024Q4
343
52.59M
87.55%
+1.63M
2024Q3
334
50.95M
89.20%
-1.08M
2024Q2
328
52.17M
86.99%
+2.08M
2024Q1
314
50.10M
82.52%
-553.42K
2023Q4
296
45.99M
83.45%
+2.48M
2023Q3
294
41.91M
82.26%
+3.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
4.20M
6.49%
+546.58K
+14.97%
Jun 30, 2025
Tang Capital Management, LLC
5.00M
7.73%
--
--
Jun 30, 2025
Lynch (Timothy Patrick)
4.09M
6.33%
+4.09M
--
Aug 11, 2025
Caligan Partners, LP
3.34M
5.17%
+610.82K
+22.36%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.65M
5.64%
-175.30K
-4.58%
Jun 30, 2025
The Vanguard Group, Inc.
3.31M
5.11%
+84.18K
+2.61%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
2.44M
3.77%
+2.44M
--
Jun 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Millennium Management LLC
1.48M
2.29%
+91.40K
+6.57%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Pharmaceuticals ETF
0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.93%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
View more
State Street SPDR S&P Pharmaceuticals ETF
Proportion0.97%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.93%
iShares U.S. Pharmaceuticals ETF
Proportion0.15%
iShares Micro-Cap ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Hedge Replication ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Evolus Inc?
The top five shareholders of Evolus Inc are:
Nantahala Capital Management, LLC holds 4.20M shares, accounting for 6.49% of the total shares.
Tang Capital Management, LLC holds 5.00M shares, accounting for 7.73% of the total shares.
Lynch (Timothy Patrick) holds 4.09M shares, accounting for 6.33% of the total shares.
Caligan Partners, LP holds 3.34M shares, accounting for 5.17% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.65M shares, accounting for 5.64% of the total shares.
Nantahala Capital Management, LLC holds 4.20M shares, accounting for 6.49% of the total shares.
Tang Capital Management, LLC holds 5.00M shares, accounting for 7.73% of the total shares.
Lynch (Timothy Patrick) holds 4.09M shares, accounting for 6.33% of the total shares.
Caligan Partners, LP holds 3.34M shares, accounting for 5.17% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.65M shares, accounting for 5.64% of the total shares.
What are the top three shareholder types of Evolus Inc?
The top three shareholder types of Evolus Inc are:
Nantahala Capital Management, LLC
Tang Capital Management, LLC
Lynch (Timothy Patrick)
Nantahala Capital Management, LLC
Tang Capital Management, LLC
Lynch (Timothy Patrick)
How many institutions hold shares of Evolus Inc (EOLS)?
As of 2025Q4, 356 institutions hold shares of Evolus Inc, with a combined market value of approximately 58.38M, accounting for 89.22% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.98%.
What is the biggest source of revenue for Evolus Inc?
In --, the -- business generated the highest revenue for Evolus Inc, amounting to -- and accounting for --% of total revenue.
